(UroToday.com) Penile cancer is a rare malignancy with an annual incidence of 0.1-0.7 in 100,000 men, which accounts for fewer than 1% of male cancers in the United States. Treatment is often associated with considerable mutilation and changes to quality of life. Organ sparing surgery for the management of localized penile cancer has the potential to maintain penile form and function while achieving equivalent oncologic control as partial or total penectomy. Furthermore, Mohs surgery is efficacious for the treatment of non-genital and cutaneous cancers first pioneered by Dr. Mohs for penile carcinoma in 1992 with a 5-year control rate of 94%. Although it is endorsed by the National Comprehensive Cancer Network (NCCN) guidelines for low-stage penile cancer management, there is a paucity of data on cancer outcomes in localized penile cancer. At the 2020 virtual annual meeting, 4th-year medical student Nicolas Alcala presented institutional work assessing oncologic outcomes in patients with localized penile carcinoma managed with Mohs surgery.